ScreenerHero

ATHE Alterity Therapeutics Limited

NAS · US · Healthcare · Biotechnology · alteritytherapeutics.com
3.370USD+4.66%Mkt Cap: 61.36M $P/E: —

Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.24BUSDP/E 29.3
REGN
Regeneron Pharmaceuticals, Inc.
$76.05BUSDP/E 18.3
MRNA
Moderna, Inc.
$74.84BUSD
ARGX
argenx SE
$56.77BUSDP/E 37.1
ARGX
argenx SE
$58.21BUSDP/E 35.5
UCB
UCB SA
$41.93BUSDP/E 17.9
RVMD
Revolution Medicines, Inc.
$42.84BUSD
ONC
BeOne Medicines AG
$41.27BUSDP/E 64.9
RPRX
Royalty Pharma plc
$32.61BUSDP/E 30.0
ALNY
Alnylam Pharmaceuticals, Inc.
$29.97BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.66BUSD
BNTX
BioNTech SE
$24.05BUSD
GMAB
Genmab A/S
$23.24BUSDP/E 29.8
GMAB
Genmab A/S
$22.23BUSDP/E 30.6
INSM
Insmed Incorporated
$22.98BUSD
INCY
Incyte Corporation
$22.85BUSDP/E 14.4
JAZZ
Jazz Pharmaceuticals plc
$15.02BUSDP/E 15.9
ASND
Ascendis Pharma A/S
$14.87BUSDP/E 17.3
EXEL
Exelixis, Inc.
$14.45BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$13.81BUSD

Key Statistics

Company
Market Cap61.36M USD
Enterprise Value24.24M USD
Revenue (TTM)3.61M USD
Gross Profit3.35M USD
Net Income (TTM)-23.40M USD
Revenue/Share0.20 USD
Last Price3.370 USD
Fiscal Year EndJun 2026
MR QuarterJun 2026
Employees11
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.52
PEG—
EV/EBITDA-0.97
EV/Revenue6.71
P/S17.00
P/B2.07
EPS (TTM)-0.90
EPS (Forward)-0.96
52W Range
2.66022% of range5.890
52W High5.890 USD
52W Low2.660 USD
Profitability
Gross Margin92.72%
Oper. Margin-1816.16%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-54.77%
ROA-50.85%
Growth
Revenue Growth-79.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-22.52M USD
CapEx (TTM)—
FCF Margin-408.32%
FCF Yield-24.02%
Net Debt-37.12M USD
Net Debt/EBITDA1.48
Balance Sheet
Debt/Equity0.00
Current Ratio14.52
Quick Ratio14.26
Book Value/Sh1.63 USD
Cash/Share2.05 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateJan 9, 2023
Analyst Consensus
Rating—
Target (Mean)13.25 USD
Upside (mean)+293.2%
Target Range10.00 USD – 16.00 USD
10.00+293.2% to mean16.00
# Analysts4
Ownership
Shares Out.18.21M
Float14.28M
Insiders0.00%
Institutions2.07%
Short Interest
Short Ratio1.2d
Short % Float0.14%
Short % Out.0.14%
Shares Short25.66K
Short (prev mo.)24.76K
Technical
SMA 504.226 (-20.3%)
SMA 2004.040 (-16.6%)
Beta-0.01
S&P 52W Chg16.45%
Avg Vol (30d)20.72K
Avg Vol (10d)23.28K
Technical Indicators
RSI (14)36.6
MACD-0.2846
MACD Signal-0.2607
MACD Hist.-0.0239
BB Upper4.556 USD
BB Middle3.793 USD
BB Lower3.031 USD
BB Width40.18%
ATR (14)0.2956 USD
Vol Ratio (20d)1.07x